BCTX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 11:11):

Stats
Today's Volume	3 671.00
Average Volume	87 801.00
Market Cap	36.21M
EPS	$0 ( 2024-03-20 )
Next earnings date	( $-0.200 ) 2024-06-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.87
ATR14	$0.0410 (1.84%)

Insider Trading

Date	Person	Action	Amount	type
2022-12-28	Bondarenko Jamieson	Buy	28 000	Common Shares
2022-12-23	Williams William V.	Buy	2 530	Warrant
2022-12-20	Bondarenko Jamieson	Buy	22 000	Common Shares
2022-08-01	Bondarenko Jamieson	Sell	0	Common Shares
2021-03-29	Bondarenko Jamieson	Sell	150 000	Option (Right to Buy)

INSIDER POWER
-69.64
Last 25 transactions
Buy: 52 530 \| Sell: 1 209 572

Volume Correlation

Long: -0.11 (neutral)

Short: -0.65 (weak negative)

Signal:(51.973) Neutral

BriaCell Therapeutics Correlation

10 Most Positive Correlations
SUMR	0.903
RBNC	0.896
USCR	0.893
MLVF	0.892
TACO	0.892
SKYX	0.887
HWCC	0.885
AMYT	0.885
VBNK	0.883
MSON	0.879

10 Most Negative Correlations
TCDA	-0.925
THTX	-0.916
MRTX	-0.905
VERA	-0.901
LARK	-0.892
SMMF	-0.888
ODT	-0.877
KPTI	-0.876
GRCL	-0.875
HECCU	-0.869

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BriaCell Therapeutics Correlation - Currency/Commodity

0.22
( neutral )

0.00
( neutral )

0.42
( neutral )

-0.07
( neutral )

-0.45
( neutral )

BriaCell Therapeutics Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-15 529.00 (0.00 %)
EPS:	$-1.300

Q4	2023
Revenue:	$0
Gross Profit:	$-3 861.57 (0.00 %)
EPS:	$-0.150

Q3	2023
Revenue:	$0
Gross Profit:	$-3 816.34 (0.00 %)
EPS:	$-0.280

Q2	2023
Revenue:	$0
Gross Profit:	$-3 865.55 (0.00 %)
EPS:	$-0.770

Financial Reports:

No articles found.

BriaCell Therapeutics

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.